AU2013254690B2 - Anti-PDGF-C antibodies - Google Patents

Anti-PDGF-C antibodies Download PDF

Info

Publication number
AU2013254690B2
AU2013254690B2 AU2013254690A AU2013254690A AU2013254690B2 AU 2013254690 B2 AU2013254690 B2 AU 2013254690B2 AU 2013254690 A AU2013254690 A AU 2013254690A AU 2013254690 A AU2013254690 A AU 2013254690A AU 2013254690 B2 AU2013254690 B2 AU 2013254690B2
Authority
AU
Australia
Prior art keywords
antibody
seq
pdgf
amino acid
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2013254690A
Other languages
English (en)
Other versions
AU2013254690A1 (en
Inventor
Claudia Fromond
Hoa Thu NGO
Sofie NOTEBAERT
Richard Zwaal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxurion NV
Original Assignee
ThromboGenics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ThromboGenics NV filed Critical ThromboGenics NV
Publication of AU2013254690A1 publication Critical patent/AU2013254690A1/en
Application granted granted Critical
Publication of AU2013254690B2 publication Critical patent/AU2013254690B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013254690A 2012-04-24 2013-04-24 Anti-PDGF-C antibodies Expired - Fee Related AU2013254690B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261637372P 2012-04-24 2012-04-24
US61/637,372 2012-04-24
EP12165314 2012-04-24
EP12165314.1 2012-04-24
US201261727231P 2012-11-16 2012-11-16
US61/727,231 2012-11-16
EP12192943.4 2012-11-16
EP12192943 2012-11-16
PCT/EP2013/058513 WO2013160359A1 (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Publications (2)

Publication Number Publication Date
AU2013254690A1 AU2013254690A1 (en) 2014-11-06
AU2013254690B2 true AU2013254690B2 (en) 2017-12-07

Family

ID=49482233

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013254690A Expired - Fee Related AU2013254690B2 (en) 2012-04-24 2013-04-24 Anti-PDGF-C antibodies

Country Status (13)

Country Link
US (1) US9884910B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2841454A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2015515487A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150005631A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104321343A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013254690B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014025560A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2871528A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN09717A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2014012843A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ724395A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2014140116A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013160359A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321343A (zh) 2012-04-24 2015-01-28 斯鲁姆博詹尼克斯公司 抗pdgf-c抗体
WO2017081171A1 (en) * 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
MA45493A (fr) * 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
US11352420B2 (en) 2016-07-01 2022-06-07 Paracrine Therapeutics Ab Methods and compositions for PDGF-CC inhibition
KR101943083B1 (ko) 2017-03-30 2019-01-29 (주)케어젠 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2020005809A (es) * 2017-12-04 2020-08-20 Salvat Lab Sa Composicion topica oftalmica para tratar enfermedades del segmento posterior del ojo.
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
WO2025038442A1 (en) * 2023-08-11 2025-02-20 Invetx, Inc. Anti-il-5 antibodies and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011742A1 (en) * 2003-07-25 2005-02-10 Zymogenetics, Inc. Method of treating hepatocellular carcinoma

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1991019515A1 (en) 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
CN1330664A (zh) 1998-09-30 2002-01-09 路德维格癌症研究所 血小板衍生生长因子c、其编码dna及其应用
DK1137773T3 (da) * 1998-12-07 2008-12-08 Zymogenetics Inc Væsktfaktorhomolog ZVEGF3
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2001028586A1 (en) 1999-10-21 2001-04-26 Zymogenetics, Inc. Method of treating fibrosis
US7034200B2 (en) * 2000-03-28 2006-04-25 Ludwig Institute For Cancer Research Non-human transgenic animals expressing platelet-derived growth factor C (PDGF-C) and uses thereof
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
WO2007124308A2 (en) 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
CN104321343A (zh) 2012-04-24 2015-01-28 斯鲁姆博詹尼克斯公司 抗pdgf-c抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011742A1 (en) * 2003-07-25 2005-02-10 Zymogenetics, Inc. Method of treating hepatocellular carcinoma

Also Published As

Publication number Publication date
WO2013160359A1 (en) 2013-10-31
CN104321343A (zh) 2015-01-28
MX2014012843A (es) 2017-01-23
JP2015515487A (ja) 2015-05-28
EP2841454A1 (en) 2015-03-04
RU2014140116A (ru) 2016-06-10
NZ700274A (en) 2016-10-28
CA2871528A1 (en) 2013-10-31
US20150232546A1 (en) 2015-08-20
US9884910B2 (en) 2018-02-06
KR20150005631A (ko) 2015-01-14
BR112014025560A2 (pt) 2017-07-04
IN2014DN09717A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-31
AU2013254690A1 (en) 2014-11-06
NZ724395A (en) 2018-03-23

Similar Documents

Publication Publication Date Title
AU2013254690B2 (en) Anti-PDGF-C antibodies
US20230013364A1 (en) Combination therapies comprising antibody molecules to pd-1
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
CN103533960B (zh) c-KIT抗体及其用途
US11155615B2 (en) Anti-ROR1 antibodies
EP2220121B1 (en) Axl antibodies
RU2571224C2 (ru) Гуманизированные антитела против axl
KR20190035863A (ko) 암 치료를 위한 항Siglec-7 항체
EP3825330A1 (en) Anti-cd117 antibodies and methods of use thereof
KR20180042335A (ko) 조합 및 이의 용도
WO2021139682A1 (en) Anti-galectin-9 antibody and uses thereof
JP7094329B2 (ja) 低悪性度漿液性癌におけるher3阻害
US20230183379A1 (en) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
CN113874036A (zh) 使用cdk抑制剂的联合治疗
US20240368260A1 (en) HUMANIZED ANTI-HUMAN ßIG-H3 PROTEIN AND USES THEREOF
WO2023143444A1 (zh) 抗dkk1抗体、其药物组合物及用途
WO2017015008A1 (en) Her3 antibodies
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
US20250296989A1 (en) ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
WO2013139956A1 (en) Antibodies abrogating cell binding to lactadherin
US20150152193A1 (en) Axl antibodies
US20240141060A1 (en) Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee